Dynamics of drug response informs rational combination regimens.

Metabolic plasticity in cancer has been linked to the development of drug-tolerant populations. In this issue of Science Signaling, Goldman et al integrate metabolic plasticity with phenotypic state transitions to examine how this reprogramming can be therapeutically exploited.